NDAORALTABLET
Approved
Jun 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
4/8 — Partial
PROVERA (medroxyprogesterone acetate) by Pfizer is (mpa) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. First approved in 1959.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROVERA (medroxyprogesterone acetate) is a synthetic progestin oral tablet approved in 1959 that inhibits gonadotropin secretion to prevent follicular maturation and ovulation. It is indicated for contraception, endometrial cancer/hyperplasia, menopause symptoms, osteoporosis, menorrhagia, prostate cancer, endometriosis, and several other conditions. The drug works by thickening cervical mucus and suppressing reproductive hormones across multiple therapeutic domains.
$34KPart D
LOE ApproachingDeclining
As an LOE-approaching mature product with minimal Part D spending, PROVERA team size is likely small and focused on managed care defense rather than growth initiatives.
Mechanism of Action
(MPA) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
Started Dec 2020
60 enrolled
Contraception
Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers
Started Mar 2018
460 enrolled
Contraception
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Started Mar 2017
24 enrolled
Contraception
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Started Oct 2016
12 enrolled
PregnancyContraception
Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood
Started Aug 2015
401 enrolled
Contraception
Worked on PROVERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.